Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2014. The report details a specific share repurchase transaction executed on May 23, 2014, pursuant to shareholder authority granted at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 485,250 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,629.00 pence per share; lowest price paid was 1,616.00 pence per share.
- Treasury Holdings (Settled): 493,013,312 shares (9.21% of total issued share capital).
- Treasury Holdings (Including Unsettled): 493,929,462 shares (10.17% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,857,557,666 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 485,250 shares for treasury. Consequently, the percentage of shares held in treasury increased to 10.17% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure under the Financial Conduct Authority's Disclosure and Transparency Rules regarding share ownership and voting rights calculations.
Investor Verification Points
- Verify the total number of shares in issue (4,857,557,666) for calculating disclosure thresholds under FCA rules.
- Confirm the current percentage of voting rights held in treasury (10.17% including unsettled shares).
- Note that the repurchase price range (1,616.00 to 1,629.00 pence) reflects market conditions on May 23, 2014.